Yosemite, an oncology-focused venture fund, has secured $80.0 million in new investment capital from investors. This funding round marks a significant milestone for the firm, which focuses on advancing biotech and healthcare innovations aimed at making cancer non-lethal.
Founded by Reed Jobs in 2015, Yosemite originated within Emerson Collective before establishing its independence in 2023. The fund operates with a distinctive investment model that redefines the traditional academic-industry partnership. It strategically deploys philanthropic capital to seed pioneering scientific research, thereby strengthening its collaborations with academic institutions. This approach provides Yosemite with early access to investable science within the commercialization pipeline.
The $80.0 million in capital will enable Yosemite to significantly expand its investment activities. The funds are earmarked for deployment into promising biotech and healthcare innovations, particularly those focused on oncology. This investment underscores investor confidence in Yosemite's unique model and its mission to accelerate breakthroughs in cancer treatment and prevention. The capital will be crucial for identifying and supporting early-stage research and development efforts that align with the fund's objective of transforming cancer care.
With this new capital, Yosemite is well-positioned to deepen its impact within the oncology landscape. The firm plans to continue fostering its collaborative ecosystem, driving further innovation, and ultimately contributing to the development of solutions that address the critical challenges in cancer. This funding round is expected to bolster Yosemite's capacity to support a broader portfolio of ventures dedicated to making cancer a manageable or curable condition.
